Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
暂无分享，去创建一个
L. Resnick | J. Timpone | M. Fischl | W. Powderly | L. Demeter | R. Reichman | M. Para | G. Morse | S. Cox | D. Batts | J. Leedom | Y. Bassiakos